02528nas a2200361   4500000000100000008004100001260001300042653001200055653002400067653001700091653000900108653003800117653004500155653001100200653002100211653002800232653003200260653002000292100002200312700002200334700001300356700001300369700001700382700001400399700001300413700001600426245011900442856006900561300001100630490000600641520150500647022001402152       2002                            d  c2002 Nov10aAnimals10aAntigens, Protozoan10aDog Diseases10aDogs10aEnzyme-Linked Immunosorbent Assay10aFluorescent Antibody Technique, Indirect10aHumans10aLeishmania major10aLeishmaniasis, Visceral10aSensitivity and Specificity10aSerologic Tests1 aBarbosa-De-Deus R1 aDos Mares-Guia ML1 aNunes AZ1 aCosta KM1 aJunqueira RG1 aMayrink W1 aGenaro O1 aTavares CAP00aLeishmania major-like antigen for specific and sensitive serodiagnosis of human and canine visceral leishmaniasis.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC130090/pdf/0038.pdf  a1361-60 v93 a<p>An antigen (LMS) prepared from Leishmania major-like promastigotes was used in an enzyme-linked immunosorbent assay (ELISA) for the diagnosis of human and dog visceral leishmaniasis. The results were compared with those from the indirect immunofluorescent antibody test (IFAT). A total of 1822 canine sera were tested, including sera from dogs with visceral leishmaniasis, transmissible venereal tumors, ehrlichiosis, rickettsiosis, or Chagas' disease and sera from healthy dogs. The antigen was also tested with 227 samples of human sera, including sera from patients with visceral, cutaneous, or diffuse cutaneous leishmaniasis and from noninfected individuals, as well as sera from patients with Chagas' disease, toxoplasmosis, rickettsiosis, hepatitis B, schistosomiasis, ascaridiasis, malaria, rheumatoid factor, leprosy and rheumatoid factor, tuberculosis, or leprosy. All dogs and all human patients had a clinical and/or serological and/or parasitological diagnosis. For detecting antibodies in sera from dogs with leishmaniasis, the antigen showed a sensitivity of 98%, specificity of 95%, and concordance of 93% and when used for detecting antibodies in human sera presented a sensitivity of 92%, specificity of 100%, and concordance of 92%. Comparison between ELISA and IFAT demonstrated that ELISA using the LMS antigen yielded more reliable results than IFAT. The LMS antigen displayed no cross-reactivity with sera from patients or dogs that had any of the other diseases tested.</p>  a1071-412X